AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer's disease by AC Immune's partner, LMI T

AC Immune's PI-2620 Tau-PET Diagnostic

Fast Track Designation in Three Neurodegenerative Conditions

Lausanne, Switzerland, August 28, 2024 -

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases,

today announced that its partner Life Molecular Imaging (LMI) has received Fast Track Designation for the Tau positron emission tomography

(PET) diagnostic, [18F]PI-2620, from the U.S. Food and Drug Administration (FDA) in three neurodegenerative conditions.

Fast Track designation for [18F]PI-2620 has been

granted for clinical development in Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration

The FDA's Fast Track program is designed

to accelerate the development and review of drugs that address serious conditions and fulfill unmet medical needs. This designation underscores

the broadening view in the medical community that early and accurate diagnoses of neurodegenerative disease may lead to improved outcomes,

thanks to emerging treatments.

PI-2620 is a next-generation PET imaging agent

currently in Phase 3 clinical development for detecting Tau pathology in Alzheimer's disease. The compound is also being investigated

in other neurodegenerative diseases by many academic researchers and in drug development trials. Tau proteins are a hallmark of several

neurodegenerative disorders including AD, PSP, CBD, and frontotemporal lobar dementia (FTLD), and accurately imaging the pathology could

significantly enhance disease diagnosis and improve patient care.

Dr. Andrea Pfeifer, CEO of AC

Immune SA, commented: "Fast Track designation for PI-2620 is an important reflection of its potential to accurately diagnose

Alzheimer's and other neurodegenerative diseases. Early diagnosis of these conditions will be key for effective treatment before

irreversible damage occurs, and is an essential element in our goal of achieving precision prevention. The FDA has previously granted

Fast Track status to two of our active immunotherapies in Phase 2 development, ACI-35.030 and ACI-24.060, which target phospho-Tau and

Abeta, respectively. The designation for PI-2620 is a further recognition of AC Immune's drug discovery and development platform

and of how we, together with our partners, continue to drive innovation."

PI-2620 was discovered

and developed as part of a research collaboration between AC Immune and LMI. LMI has the exclusive, worldwide license for research, development

and commercialization of Tau-PET tracers generated within the discovery program. It has demonstrated robust brain uptake and fast wash-out

in non-target regions, a broad imaging window between 30- and 90-minutes post-injection for AD, and excellent reproducibility between

test and retest scans. The absence of significant off-target binding enables PI-2620 to detect and quantify early Tau deposition in the

brain, a hallmark of neurodegenerative diseases. PI-2620 is currently under investigation in several clinical studies as a targeted radiopharmaceutical

for the detection of Tau deposits in the human brain. PI-2620 also shows promise for non-AD tauopathies like progressive supranuclear

palsy (PSP) and corticobasal syndrome (CBS).

AC Immune SA is a clinical-stage biopharmaceutical

company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's

disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms,

SupraAntigen and Morphomer , fuel its broad and diversified pipeline of first- and best-in-class assets,

which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune

has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive

funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

SupraAntigen is a registered trademark

of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer is a registered trademark

of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites

referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Forward looking statements

This press release contains statements that constitute

"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities

Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future

operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements

by forward-looking words such as "may," "might," "will," "should," "expects,"

"plans," "anticipates," "believes," "estimates," "predicts," "projects,"

"potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements

are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual

results, developments

and business decisions to differ materially from

those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information

- Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report

on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they

are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise,

except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.